Industry Overview - Collagen masks are mainstream skincare products focused on anti-aging and repair, utilizing collagen as the core ingredient along with auxiliary components to achieve hydration and skin barrier repair [1][2] - The Chinese mask industry is expected to reach a market size of 72.986 billion yuan in 2024, entering a period of adjustment and transformation, facing growth slowdown and intensified competition [1][6] - The collagen market is experiencing explosive growth, with a compound annual growth rate (CAGR) of 41.9% from 2020 to 2023, and retail scale expected to exceed 269.5 billion yuan by 2030 [1][7] Market Dynamics - The market structure in China shows that sheet masks remain dominant, while cream masks are rapidly growing, focusing on hydration and repair needs [1][7] - The competitive landscape features local leaders dominating, niche players breaking through, and international brands penetrating the market, with a clear price gradient and significant differentiation between high, medium, and low-end markets [1][8] Industry Chain - The upstream of the collagen mask industry primarily uses animal-derived collagen, while recombinant collagen is rapidly developing due to its high purity and compatibility with mask formulations [6][10] - The manufacturing process involves various technologies to convert raw materials into different forms and functions of mask products, with sales channels dominated by online e-commerce and deepening offline professional channels [6][10] Current Development - The Chinese mask industry is transitioning into a phase of deep integration after rapid growth, with three emerging drivers leading market changes: consumption upgrades, male skincare market expansion, and personalized demand fostering innovative scenarios [6][7] - The market size is projected to steadily grow to 76.79 billion yuan by 2025 and potentially exceed 146.42 billion yuan by 2030, indicating robust long-term growth prospects [6][7] Key Players - Major companies in the collagen mask industry include Juzi Biotechnology, Huaxi Biotechnology, and Marubi Biotechnology, leveraging differentiated technologies and channel advantages to lead the market [2][10] - The industry is characterized by a multi-faceted competitive ecosystem, with local leaders, niche players, and international brands all contributing to the market dynamics [10] Future Trends - The industry is expected to advance towards high-end technology, refined products, and standardized ecosystems, with a focus on cross-disciplinary technology integration and precise formulations [10][12] - Regulatory tightening is anticipated to accelerate the elimination of smaller brands, increasing market concentration, while leading companies will strengthen their market positions through R&D innovation and global expansion [10][14]

证券代码：688105 证券简称：诺唯赞 公告编号：2025-055 南京诺唯赞生物科技股份有限公司2025年第二次临时股东会决议公告 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容的 真实性、准确性和完整性依法承担法律责任。 重要内容提示： ● 本次会议是否有被否决议案：无 一、会议召开和出席情况 （一）股东会召开的时间：2025年12月5日 （二）股东会召开的地点：南京市栖霞区科创路红枫科技园D2栋1楼报告厅 （三）出席会议的普通股股东、特别表决权股东、恢复表决权的优先股股东及其持有表决权数量的情 况： 表决情况： ■ ■ （四）表决方式是否符合《公司法》及公司章程的规定，股东会主持情况等。 本次股东会由公司董事会召集，董事长曹林先生主持，会议采用现场投票和网络投票相结合的表决方 式。本次股东会的召集和召开程序、出席会议人员资格和召集人资格、会议表决方式和表决结果均符合 《中华人民共和国公司法》及《公司章程》的规定。 （五）公司董事和董事会秘书的列席情况 1、公司在任董事9人，列席8人，独立董事蔡江南先生因公请假，未列席本次会议。 2、董事会秘书黄金先生列席本次会 ...

北京市天元律师事务所 京天股字（2025）第 723 号 致：南京诺唯赞生物科技股份有限公司 南京诺唯赞生物科技股份有限公司（以下简称"公司"）2025 年第二次临时股 东会（以下简称"本次股东会"）采用现场投票与网络投票相结合的方式召开，现场 会议于 2025 年 12 月 5 日下午 15:00 在南京市栖霞区科创路红枫科技园 D2 栋公司 1 楼报告厅召开。北京市天元律师事务所（以下简称"本所"）接受公司聘任，指派 本所律师参加本次股东会现场会议，并根据《中华人民共和国公司法》、《中华人民 共和国证券法》（以下简称"《证券法》"）、《上市公司股东会规则》（以下简称"《股 东会规则》"）以及《南京诺唯赞生物科技股份有限公司章程》（以下简称"《公司 章程》"）等有关规定，就本次股东会的召集、召开程序、出席会议人员的资格、 召集人资格、会议表决程序和表决结果等有关事宜出具本法律意见。 为出具本法律意见，本所律师审查了《南京诺唯赞生物科技股份有限公司第二 届董事会第二十次会议决议公告》、《南京诺唯赞生物科技股份有限公司关于召开 2025 年第二次临时股东会的通知》（以下简称"《召开股东会通知》"）以及本所律 师 ...

证券代码：688105 证券简称：诺唯赞 公告编号：2025-055 南京诺唯赞生物科技股份有限公司 2025年第二次临时股东会决议公告 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 本次会议是否有被否决议案：无 一、 会议召开和出席情况 | 1、出席会议的股东和代理人人数 | 71 | | --- | --- | | 普通股股东人数 | 71 | | 2、出席会议的股东所持有的表决权数量 | 232,121,546 | | 普通股股东所持有表决权数量 | 232,121,546 | | 3、出席会议的股东所持有表决权数量占公司表决权数量的 | 58.3797 | | 比例（%） | | | 普通股股东所持有表决权数量占公司表决权数量的比例（%） | 58.3797 | 2、 董事会秘书黄金先生列席本次会议。 （四） 表决方式是否符合《公司法》及公司章程的规定，股东会主持情况等。 本次股东会由公司董事会召集，董事长曹林先生主持，会议采用现场投票和 网络投票相结合的表决方式。本次股东会的召集和召开程序、出席会 ...

Core Points - The stock price of NuoVivian has decreased by 2.07% to 21.76 CNY per share, with a total market capitalization of 8.655 billion CNY [1] - The company has experienced a year-to-date stock price decline of 1.18%, with a 4.27% drop over the last five trading days [1] - NuoVivian's main business includes the research and development of functional proteins and high molecular organic materials, with a revenue composition of 81.86% from biological reagents [1] Financial Performance - As of September 30, NuoVivian reported a total of 9,447 shareholders, an increase of 9.90% from the previous period [2] - For the period from January to September 2025, the company achieved a revenue of 952 million CNY, a year-on-year decrease of 3.40% [2] - The net profit attributable to the parent company was 6.6152 million CNY, reflecting a significant year-on-year decrease of 63.57% [2] Dividend Information - Since its A-share listing, NuoVivian has distributed a total of 731 million CNY in dividends, with 611 million CNY distributed over the past three years [3]

证券代码：688105 证券简称：诺唯赞 公告编号：2025-054 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： | 回购方案首次披露日 | 2025/6/20 | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | | 回购方案实施期限 | 2025 6 6 月 | 年 | 月 | 19 | 日~2026 | 年 | 18 日 | | 预计回购金额 | 500万元~1,000万元 | | | | | | | | 回购用途 | □减少注册资本 √用于员工持股计划或股权激励 | | | | | | | | | □用于转换公司可转债 | | | | | | | | | □为维护公司价值及股东权益 | | | | | | | | 累计已回购股数 | 12.77万股 | | | | | | | | 累计已回购股数占总股本比例 | 0.03% | | | | | | | | 累计已回购金额 | 299.97万元 | | | | | | | | 实 ...

格隆汇12月1日丨诺唯赞(688105.SH)公布，截至2025年11月30日，公司通过上海证券交易所交易系统以 集中竞价交易方式累计回购公司股份12.77万股，占公司总股本的比例为0.03%，回购成交的最高价为 24.36元/股，最低价为23.06元/股，支付的资金总额为人民币299.97万元（不含印花税、交易佣金等交易 费用）。 ...

Core Insights - The aging population in China is leading to an increase in Alzheimer's Disease (AD) cases, with approximately 17 million patients currently diagnosed, most at advanced stages by the time of clinical confirmation [2][3] - Innovative breakthroughs in early screening technologies, particularly by the biotech company NuoVizon, have resulted in the approval of seven blood test kits for early diagnosis of AD and other neurodegenerative diseases, significantly advancing the field [2][3] Group 1: Company Innovations - NuoVizon has received approval for seven blood test kits that cover early diagnosis of AD and Parkinson's Disease (PD), with five biomarkers filling industry gaps, thus providing innovative solutions for early screening and diagnosis [2][3] - The company has previously obtained regulatory approval for six AD blood test kits, achieving a sensitivity of over 0.5 pg/ml, which allows for earlier intervention in AD treatment by moving the "golden window" for diagnosis forward by 10-20 years [2][3] Group 2: Market Potential - The blood testing method developed by NuoVizon is characterized by its minimally invasive, convenient, and cost-effective nature, making it suitable for large-scale population screening, which could unlock significant market potential [5] - The application scenarios for AD blood tests are extensive, ranging from screening high-risk populations to inclusion in health check-ups and dynamic monitoring of treatment efficacy, representing both a commercial opportunity and a public health initiative [5] Group 3: Industry Positioning - NuoVizon has established itself as a benchmark in the AD diagnostic field, having entered over 300 hospitals and research institutions within a year of product launch, supported by rigorous academic validation and clinical recognition [4] - The company aims to develop a comprehensive AD blood testing standard tailored to the Chinese population, collaborating with leading medical experts and integrating resources across the industry to enhance the accessibility of its innovations [4] Group 4: Future Outlook - NuoVizon plans to expand its AD blood test product line and focus on developing precise diagnostic products for other central nervous system diseases, positioning itself as a leading brand in blood diagnostics for neurodegenerative diseases [6] - The onset of the "blood testing era" for neurodegenerative disease diagnosis is accelerating, with NuoVizon expected to play an increasingly significant role in global brain health strategies, warranting ongoing attention to its future developments [6]

南京诺唯赞生物科技股份有限公司 2025 年第二次临时股东会 会议资料 2025 年 12 月 南京诺唯赞生物科技股份有限公司 2025 年第二次临时股东会会议资料 南京诺唯赞生物科技股份有限公司 2025 年第二次临时股东会会议须知 为维护全体股东合法权益，确保股东会的正常秩序和议事效率，保证股东会 的顺利进行，根据《中华人民共和国公司法》《中华人民共和国证券法》、中国 证券监督管理委员会《上市公司股东会规则》以及《南京诺唯赞生物科技股份有 限公司章程》《南京诺唯赞生物科技股份有限公司股东会议事规则》等有关规定， 南京诺唯赞生物科技股份有限公司（以下简称"公司"）特制定本次股东会会议 须知： 一、董事会在股东会召开过程中，应当以维护股东的合法权益、确保正常程 序和议事效率为原则，认真履行法定职责。股东会设立秘书处，负责会议有关程 序方面事宜。 二、各股东（含股东代理人，下同）请按照本次股东会会议通知中规定的时 间和登记方法办理参会手续，详见公司刊登于上海证券交易所网站 （www.sse.com.cn）的《关于召开 2025 年第二次临时股东会的通知》（公告编 号：2025-051），证明文件不齐或手续不全的 ...

证券日报网讯 11月20日晚间，诺唯赞发布公告称，南京诺唯赞生物科技股份有限公司（以下简称"公 司"）于近日召开职工代表大会，民主选举张国洋先生为公司第二届董事会职工董事。 ...